Decreased Serum Level of Interleukin-22 Correlates with Hepcidin in Patients with Hidradenitis Suppurativa.


Journal

Acta dermato-venereologica
ISSN: 1651-2057
Titre abrégé: Acta Derm Venereol
Pays: Sweden
ID NLM: 0370310

Informations de publication

Date de publication:
22 Sep 2021
Historique:
pubmed: 14 9 2021
medline: 25 9 2021
entrez: 13 9 2021
Statut: epublish

Résumé

Current understanding of the underlying pathophysiology of hidradenitis suppurativa (HS) links the disease with proinflammatory activation and autoimmune processes. This study investigated serum levels of interleukin (IL)-22, a cytokine critically involved in epithelial homeostasis, in the context of the broad clinical spectrum of patients with HS. The study also assessed the relationship between serum IL-22 and pro-inflammatory activation (as evidenced by serum level of IL-6) and serum hepcidin (central regulator of systemic iron homeostasis). Serum concentrations of IL-22 were assessed in 74 patients with HS and 15 healthy subjects. Compared with healthy controls, patients with HS demonstrated decreased levels of serum IL-22 (median; interquartile range (IQR): 12.4 pg/ml (9.8; 23.5) vs 34.8 pg/ml (24.8; 39.8), p < 0.001 vs controls). Disease severity (assessed both with Hurley staging and Hidradenitis Suppurativa Severity Index) did not differentiate IL-22 levels (p > 0.1 in both comparisons). Serum levels of IL-22 and IL-6 did not correlate with each other (R=-0.17, p = ns). In a subgroup of 24 patients with HS with pro-inflammatory activation, the mean level of IL-22 was similar to that of the remaining patients (median (IQR): 9.8 pg/ml (8.5; 15.0) vs 12.0 pg/ml (9.4; 16.3), p = ns). Patients with HS demonstrated a decreased level of hepcidin (mean: 31.3 ± 25.9 pg/ml), which correlated with the levels of IL-22 (R=0.36, p <0.05). Patients with HS demonstrated significantly decreased levels of serum IL-22, which was neither correlated with pro-inflammatory status nor associated with disease severity, but correlated modestly with serum hepcidin.

Identifiants

pubmed: 34515804
doi: 10.2340/00015555-3928
pmc: PMC9425619
doi:

Substances chimiques

Cytokines 0
Hepcidins 0
Interleukins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

adv00558

Références

Nat Rev Drug Discov. 2014 Jan;13(1):21-38
pubmed: 24378801
Immunol Invest. 2018 Jan;47(1):57-70
pubmed: 28972431
Cold Spring Harb Perspect Biol. 2014 Sep 04;6(10):a016295
pubmed: 25190079
Br J Dermatol. 2011 Jun;164(6):1292-8
pubmed: 21332464
J Am Acad Dermatol. 2010 Feb;62(2):205-17
pubmed: 20115947
Ann Dermatol. 2012 Nov;24(4):393-7
pubmed: 23197903
J Am Acad Dermatol. 2015 Nov;73(5 Suppl 1):S8-11
pubmed: 26470623
J Immunol. 2013 Aug 15;191(4):1845-55
pubmed: 23836059
Dermatol Ther. 2020 Nov;33(6):e13845
pubmed: 32544258
J Eur Acad Dermatol Venereol. 2015 Apr;29(4):619-44
pubmed: 25640693
Br J Dermatol. 2009 Oct;161(4):831-9
pubmed: 19438453
Acta Derm Venereol. 2009 Nov;89(6):601-3
pubmed: 19997690
Eur Heart J. 2013 Mar;34(11):827-34
pubmed: 23178646
Clin Exp Dermatol. 1994 May;19(3):210-6
pubmed: 8033378
Acta Derm Venereol. 2010 May;90(3):264-8
pubmed: 20526543
Int J Dermatol. 2014 Oct;53(10):1186-96
pubmed: 24961484
J Invest Dermatol. 2016 Sep;136(9):1768-1780
pubmed: 27206704
JAMA. 2017 Nov 28;318(20):2019-2032
pubmed: 29183082
Autoimmun Rev. 2017 Dec;16(12):1209-1218
pubmed: 29037907
JAMA Dermatol. 2016 Jan;152(1):52-59
pubmed: 26579854
J Mol Med (Berl). 2009 May;87(5):523-36
pubmed: 19330474
J Biol Chem. 2015 Jul 31;290(31):18975-83
pubmed: 26055723
Dermatology. 2020;236(1):52-58
pubmed: 31927542
Int J Clin Exp Pathol. 2014 Jan 15;7(2):474-80
pubmed: 24551268
Immunotherapy. 2019 Jan;11(1):45-59
pubmed: 30702012
Dermatol Clin. 2016 Jan;34(1):51-8
pubmed: 26617358
J Immunol. 2011 Jan 15;186(2):1228-39
pubmed: 21148041

Auteurs

Malgorzata Ponikowska (M)

Department of Dermatology, Venerology and Allergology, Wroclaw Medical University, PL-50-368 Wroclaw, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH